Depression Presents Diagnostic Challenges in Primary Care

Distress Signals: How to Help a Clinician Colleague in Need

GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

February 14th 2023

Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Stewart Tepper, MD

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.

September 29th 2022

Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose

Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.

Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial

Your daily dose of the clinical news you may have missed.

Related Content

Grace Halsey

Distress Signals: How to Help a Clinician Colleague in Need

GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

February 14th 2023

Symbravo Mechanism of Action and Patient Selection, with PI Stewart Tepper, MD

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

Stewart Tepper, MD

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

Tepper, principal investigator for phase 3 trials of Symbravo as acute treatment for migraine in adults, reviews the new drug's dual MOA and target patient populations.

September 29th 2022

Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose

Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.